TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma

NCT04954781 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Intrahepatic Cholangiocarcinoma

Interventions

DRUG: Tislelizumab
COMBINATION_PRODUCT: TACE

Sponsor

Fudan University